Crispr Wins Its Second Gene-Editing Approval In Another Boost To Vertex Stock
Crispr Therapeutics Medical Chief Morrow to Resign
Crispr Therapeutics Medical Chief Morrow to Resign
Here's What The FDA Approval Of Gene Editing For Sickle Cell Means For CRSP Stock And The Future Of Medicine
Dow Jones Futures: Market Looks Ready To Run; 5 Stocks In Buy Zones As Tesla Sets Up
Dow Jones Futures: Market Looks Ready To Run; 5 Stocks In Buy Zones As Tesla Sets Up
Dow Jones Futures: Market Looks Ready To Run; 5 Stocks In Buy Zones As Tesla Sets Up
Crispr Therapeutics, Vertex get FDA approval for breakthrough gene-editing treatment
Health Care Climbs as Deal Wave Seen Continuing -- Health Care Roundup
Crispr Stock Whipsaws Lower After FDA Approves Gene-Editing Treatment
Stock Market Finishes Strong; CRSP Sinks On FDA News
Bluebird Bio Shares Slide 41% on Black-Box Label, Higher Price for Sickle-Cell Treatment
FDA Approves First Two Sickle Cell Gene Therapies, bluebird bio Shares Tumble
FDA Approves World’s First Crispr Gene-Editing Drug for Sickle-Cell Disease
Bluebird Bio Gets FDA OK of Lyfgenia Gene Therapy in Sickle-Cell Disease
Cathie Wood’s ARK Innovation Had a Great Month. Will It Last?
Gene Editing Will Change Medicine—and Maybe Health Investing Too
These Stocks Are Exploding In The November Stock Market Rally
Stock Market Holds Gains; CRISPR Stock Continues To Climb
CRISPR Therapeutics Stock Earns 88 RS Rating On U.K. Regulator News
Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.